Skip to main content
OpenTrials

Clinical trial condition

Digestive System Neoplasms

Explore clinical trials studying Digestive System Neoplasms. Study availability and eligibility vary by location and protocol.

14,384 public trials 3,278 recruiting studies
Refine in advanced search Browse all conditions

Digestive System Neoplasms trial results

Active, not recruiting

A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer

NCT06532331

Conditions
Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +6 more
Locations
  • Aichi Cancer Center Nagoya, Aichi-ken, Japan
  • National Cancer Center Hospital East Kashiwa-shi, Chiba, Japan
  • Kanazawa University Hospital Kanazawa, Ishikawa-ken, Japan
  • Kanagawa Cancer Center Yokohama, Kanagawa, Japan
View Trial Details
Active, not recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

NCT05919537

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +22 more
Locations
  • GenesisCare North Shore Sydney, New South Wales, Australia
  • ICON Cancer Centre South Brisbane Brisbane, Queensland, Australia
  • Southern Oncology Clinical Research Unit Adelaide, South Australia, Australia
  • Cabrini Health Malvern, Victoria, Australia
View Trial Details
Active, not recruiting

Detection of the Emergence of RAS (Rat Sarcoma Viral Oncogene Homolog) Mutations in Circulating DNA (Deoxyribonucleic Acid) in Patients With mCRC (Metastatic Colorectal Cancer) During Treatment With Anti-EGFR (Epidermal Growth Factor Receptor) Therapy

NCT03908788

Conditions
Colonic Diseases, Colorectal Neoplasms, Digestive System Diseases, +9 more
Locations
  • ICM Val d'Aurelle Montpellier, France
  • Institut du Cancer de Montpellier - Val d'Aurelle Montpellier, France
View Trial Details
Active, not recruiting

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408

Conditions
Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +20 more
Locations
  • Site 318 Phoenix, Arizona, United States
  • Site 277 Tucson, Arizona, United States
  • Site 350 Irvine, California, United States
  • Site 364 La Jolla, California, United States
View all 117 locations
View Trial Details

Related conditions